Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes

Oeksuezoglu B., Abali H., Hayran M. , Yildirim N., Budakoglu B., Zengin N.

CHEMOTHERAPY, cilt.54, ss.352-356, 2008 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 54 Konu: 5
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1159/000151630
  • Sayfa Sayıları: ss.352-356


Our aim was to evaluate the activity and toxicity of capecitabine and cisplatin (CapCisp) combination in anthracycline- and taxane-pretreated metastatic breast cancer patients. Thirty-three patients, 20-61 years of age (median 41), were included. They received Cap 2,000 mg/m(2) on days 1-14 and Cisp 60 mg/m(2) on day 1, repeated every 3 weeks. Twelve nonprogressive patients continued single-agent Cap therapy until progression or until intolerable toxicity after Cisp cessation. The disease control rate in 154 cycles was 81.8%: complete response 3.0% (n = 1), partial response 48.5% (n = 16) and stable disease 30.3% (n = 10). The median time to disease progression was 6.3 months (95% CI 3.8-8.8). The median overall survival was 11.5 months (95% CI 6.9-16.1). The only grade 3 toxicity was neutropenia, observed in 4 patients (12.1%). CapCisp has an encouraging anti-tumor activity with a low toxicity rate in anthracycline-and taxane-pretreated metastatic breast cancer patients. Copyright (C) 2008 S. Karger AG, Basel.